How have the results of the CONVERT trial and other studies, and the mechanistic/penetration features of this formulation, influenced your decision-making as it regards selecting an amikacin-based formulation for treating MAC lung disease?

How have the results of the CONVERT trial and other studies, and the mechanistic/penetration features of this formulation, influenced your decision-making as it regards selecting an amikacin-based formulation for treating MAC lung disease?

How have the results of the CONVERT trial and other studies, and the mechanistic/penetration features of this formulation, influenced your decision-making as it regards selecting an amikacin-based formulation for treating MAC lung disease?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Julie Philley, MD

Julie Philley, MD

Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas